TP53
Cellular tumor antigen p53
As of the edition of 20 October 2026, TP53 (cellular tumor antigen p53, UniProt P04637) has 10 drugs tested at it and 10 companies on the list, 3 on route A and 0 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P04637
- How well studied
- Chemical tools exist; no approved drug acts on it
- Where it sits in the cell
- Inside the cell
- Solved structures
- 323
- Disease areas
- Cancer; Blood and lymph; Immune system; Urinary and reproductive; Pregnancy and women's health; Lungs and airways; Digestive system; Skin and connective tissue
- Registered trials of its drugs
- 89
Drugs at this target
| Status | Count |
|---|---|
| Active | 4 |
| Went quiet | 1 |
| Stopped | 5 |
| Total | 10 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Navtemadlin | Active | Phase 3 | none listed |
| Idasanutlin | Stopped | Phase 3 | none listed |
| Siremadlin | Stopped | Phase 2 | none listed |
| Eprenetapopt | Stopped | Phase 3 | none listed |
| Alrizomadlin | Active | Phase 2 | none listed |
| Rezatapopt | Active | Phase 2 | none listed |
| Teprasiran | Went quiet | Phase 2 | none listed |
| CLSP-1025 | Active | Phase 1 | none listed |
| Cenersen | Stopped | Phase 2 | none listed |
| Cenersen sodium | Stopped | Phase 2 | none listed |
10 of 10 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 3 |
| Engaged | 2 |
| Undetermined | 5 |
| Total on the list | 10 |
| Company | Route |
|---|---|
| Aprea Therapeutics | Route A |
| Eleos | Route A |
| Quark Pharmaceuticals | Route A |
The other 7 companies at TP53
In the product10 companies in all; 7 are not named here, and no score is.
See the 10 companies at TP53, ranked, with the facts behind eachRequest access. Nothing is shown until you do.